Company Overview - Arcutis is a dermatology-focused biotechnology company founded over 9 years ago to address the lack of innovation in the dermatology pipeline [2] - The company's lead product, ZORYVE, is a topical PDE4 inhibitor that is currently marketed and has three different formulations approved for four diseases [2] Product Details - ZORYVE includes a cream and foam formulation for plaque psoriasis, a foam for seborrheic dermatitis, and a different cream for atopic dermatitis [2] - The company anticipates approval for an expansion of the label in atopic dermatitis in October and is conducting a study for further label expansion [3] - Arcutis is nearing the filing for a label expansion for plaque psoriasis targeting additional patient populations [3]

Arcutis Biotherapeutics (ARQT) Conference September 03, 2025 09:45 AM ET Company ParticipantsJason Jun - MD - Healthcare Investment BankingFrank Watanabe - President, CEO & DirectorLatha Vairavan - CFOJason JunGreat. Thanks everyone for joining the fireside session today with the Arcutis team. My name is Jason Jern, Managing Director in the Citi BioPharma Banking team. Today we're joined with Frank Watanabe, CEO, and Latha Vairavan, the CFO of Arcutis. Guys, thank you very much for joining today. Why don't ...